EUVIMEDEUVIMED entdecken
Crossref

Long‐Term Follow‐Up of Chidamide With Chemotherapy in Untreated Peripheral T‐Cell Lymphoma: One Single Center Real‐World Study in China

Jiajie He, Fan Xia, Lingzi Yu, Rui Zou, Qian Zhu, Xiao Zhang, Junhong Li, Danqing Kong iD, Depei Wu, Zhengming Jin, Nana Ping, Changju Qu iD

Hematological Oncology · 2026-05 · 44 (3)

DOI: 10.1002/hon.70195 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hematological Oncology, online erschienen am 02.05.2026. Verfasst von Jiajie He und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, China. Hauptthemen laut MEDLINE: Lymphoma, T-Cell, Peripheral, Benzamides, Aminopyridines, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 25 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, National Clinical Research Center for hematologic disease.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Peripheral T‐cell lymphoma (PTCL) remains a formidable challenge in clinical management. Histone deacetylase inhibitor chidamide has demonstrated its anti‐tumor effects in real‐world studies in relapsed or refractory PTCL. To evaluate the efficacy of real‐world utilization of chidamide combined with chemotherapy for untreated PTCL and explore relative prognostic factors, a cohort of 151 PTCL patients treated with chidamide combined with chemotherapy as front‐line treatment in our center were enrolled. The overall response rate (ORR) and complete remission rate (CRR) at the end of treatment were 81.5% and 67.5%. The 7‐year overall survival (OS) rate and progression‐free survival (PFS) rate were 67.6% and 49.7%, with a median follow‐up period of 21 months, showing its satisfactory efficacy and survival advantage. Most of adverse events were transient and reversible. Furthermore, several baseline characteristics of patients were relevant to prognosis. The study identified gene mutations in TET2 (30.9%), STAT (22.7%), RHOA (17.5%), TP53 (14.4%), DNMT3A (12.4%), with TP53 and DNMT3A mutations correlating with worse clinical outcomes. The identification of gene mutations contributed to personalizing treatment strategies and predicting patient outcomes. This study raised the preliminary hypothesis that chidamide‐containing front‐line therapy might be promising for PTCL patients, which warranted further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, T-Cell, PeripheralBenzamidesAminopyridinesAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleChinaFollow-Up StudiesMiddle AgedAdultAgedPrognosisYoung AdultAdolescentSurvival Rate

Stichwörter der Autor:innen

autologous stem cell transplantationchidamideepigenetic drugsfront‐line treatmentperipheral T‐cell lymphoma

Substanzen

N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamideBenzamidesAminopyridines

Autor:innen und Institutionen

  • Department of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, China.
  • National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, China.
  • Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
  • Department of Pharmacy, the First Affiliated Hospital of Soochow University, Suzhou, China.

ORCID-Profile: Danqing Kong, Changju Qu

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • National Clinical Research Center for hematologic disease
  • Soochow University
  • Top-notch young health talents

Zitieren

APA

He, J., Xia, F., Yu, L., Zou, R., Zhu, Q., Zhang, X., Li, J., Kong, D., Wu, D., Jin, Z., Ping, N., & Qu, C. (2026). Long‐Term Follow‐Up of Chidamide With Chemotherapy in Untreated Peripheral T‐Cell Lymphoma: One Single Center Real‐World Study in China. Hematological Oncology, 44(3). https://doi.org/10.1002/hon.70195

Vancouver

He J, Xia F, Yu L, Zou R, Zhu Q, Zhang X, et al. Long‐Term Follow‐Up of Chidamide With Chemotherapy in Untreated Peripheral T‐Cell Lymphoma: One Single Center Real‐World Study in China. Hematological Oncology. 2026;44(3). doi:10.1002/hon.70195

BibTeX
@article{He2026,
  author = {He, Jiajie and Xia, Fan and Yu, Lingzi and Zou, Rui and Zhu, Qian and Zhang, Xiao and Li, Junhong and Kong, Danqing and Wu, Depei and Jin, Zhengming and Ping, Nana and Qu, Changju},
  title = {Long‐Term Follow‐Up of Chidamide With Chemotherapy in Untreated Peripheral T‐Cell Lymphoma: One Single Center Real‐World Study in China},
  journal = {Hematological Oncology},
  year = {2026},
  volume = {44},
  number = {3},
  doi = {10.1002/hon.70195}
}
Kostenlos starten →